Back
Full-text
Journal article

Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies

  • Teunissen, Charlotte E. Department of Clinical Chemistry, Neurological Laboratory and Biobank, VU University Medical Center, FdG, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
  • Tumani, Hayrettin University of Ulm, Ulm 89081, Germany
  • Bennett, Jeffrey L. Departments of Neurology & Ophthalmology, University of Colorado Denver, Aurora, USA
  • Berven, Frode S. Proteomics Unit (PROBE), Department of Biomedicine, University of Bergen, Bergen 5020, Norway
  • Brundin, Lou Division Neurology, Department Clin Neuroscience, Karolinska University Hospital, Stockholm, Sweden
  • Comabella, Manuel Neurology, Centre d'Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain
  • Franciotta, Diego Laboratory of Neuroimmunology, IRCCS, “C. Mondino Neurological Institute”, Pavia, Italy
  • Federiksen, Jette L. Neurology, Glostrup Hospital, University of Copenhagen, Glostrup 2600, Denmark
  • Fleming, John O. Department of Neurology, University of Wisconsin, Madison 53705, WI, USA
  • Furlan, Roberto Clinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
  • Hintzen, Rogier Q. Neurology, Erasmus MC, Rotterdam, The Netherlands
  • Hughes, Steve G. Clinical Developement Department, Isis Pharmaceuticals, Carlsbad, California 92024, USA
  • Jimenez, Connie R. OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
  • Johnson, Michael H. Department of Neurology, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK
  • Killestein, Joep Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine and General University Hospital, Charles University, 128 21 Prague, Czech Republic
  • Krasulova, Eva Department of Neurology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
  • Kuhle, Jens Neurology and Clinical Neuroimmunology, University Hospital, University of Basel, Basel 4031, Switzerland
  • Magnone, Maria-Chiara F. Hoffmann- La Roche Pharma, Basel, Switzerland
  • Petzold, Axel Department of Neuroimmunology, UCL Institute of Neurology, Queen Square, wc1n 3bg London, UK
  • Rajda, Cecilia Department of Neurology, University of Szeged, Szeged, Hungary
  • Rejdak, Konrad Department of Experimental Pharmacology, Medical Research Center, Warsaw, MA 02451, Poland
  • Schmidt, Hollie K. Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, USA
  • van Pesch, Vincent Neurology Department UCL, Université Catholique de Louvain, Brussels CA94117, Belgium
  • Waubant, Emmanuelle Clinical Development, Lycalis sprl, 1180 Brussels, Belgium
  • Wolf, Christian Clinical Development, UCB Pharma S.A., 6020 Braine l'Alleud, Belgium
  • Deisenhammer, Florian Department of Clinical Neurology, Innsbruck Medical University, Innsbruck E1 2AT, Austria
  • Giovannoni, Gavin Queen Mary University of London, Neuroscience & Trauma Centre, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, UK
  • Hemmer, Bernhard Deptartment of Neurology, Klinikum rechts der Isar, Technische Universität, Munich 81245, Germany
Show more…
Published in:
  • Multiple Sclerosis International. - Hindawi Limited. - 2011, vol. 2011, p. 1-9
English There is a long history of research into body fluid biomarkers in neurodegenerative and neuroinflammatory diseases. However, only a few biomarkers in cerebrospinal fluid (CSF) are being used in clinical practice. Anti-aquaporin-4 antibodies in serum are currently useful for the diagnosis of neuromyelitis optica (NMO), but we could expect novel CSF biomarkers that help define prognosis and response to treatment for this disease. One of the most critical factors in biomarker research is the inadequate powering of studies performed by single centers. Collaboration between investigators is needed to establish large biobanks of well-defined samples. A key issue in collaboration is to establish standardized protocols for biobanking to ensure that the statistical power gained by increasing the numbers of CSF samples is not compromised by pre-analytical factors. Here, consensus guidelines for CSF collection and biobanking are presented, based on the guidelines that have been published by the BioMS-eu network for CSF biomarker research. We focussed on CSF collection procedures, pre-analytical factors and high quality clinical and paraclinical information. Importantly, the biobanking protocols are applicable for CSF biobanks for research targeting any neurological disease.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/224663
Statistics
Document views: 23 File downloads:
  • fulltext.pdf: 0